Health-care companies fell, but not by as much as the broad market, amid continued enthuasism for weight-loss drugs.
Gilead shares rallied after analysts at brokerage Jefferies said the biotech company will likely soon surprise investors with data from a clinical trial of an under-the-radar obesity drug.
Shares of incumbent obesity drug makers Novo Nordisk and Eli Lilly were more or less flat on the session.
Write to Rob Curran at rob.curran@dowjones.com
(END) Dow Jones Newswires
06-14-24 1727ET